From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Some of the best new research developments were highlighted at the Clinical Trials plenary session on April 20 during AAN 2016. In part 1 of this slideshow, we share results of the first four of eight trials featured. Natalia S. Rost, MD, Vice Chair of the Science Committee and Petra Kauffman, MS, member of the Science Committee, led the session.
Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
Interim Results from a Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy with Lentiviral Vector (Lenti D) for Childhood Cerebral Adrenoleukodystrophy
KINECT 3: a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies